BioCentury
ARTICLE | Strategy

Millennium outsources to Paion

March 18, 2002 8:00 AM UTC

Despite Millennium Pharmaceutical Inc.'s acquisition of cardiovascular company Cor Therapeutics Inc., it is not as well equipped as might be expected to develop therapeutics for stroke. As a consequence, the company entered a deal last week with Paion GmbH, a company with clinical development experience for stroke treatments.

Under the deal, Paion (Aachen, Germany) gains responsibility for development, including all related costs, of MLNM's MLN519 proteasome inhibitor to treat stroke and other neurological indications. MLNM, however, retains the right to opt back in for development and retains exclusive commercialization rights in North America and parts of Asia. Paion gets exclusive rights in Europe and certain Asian countries in exchange for option payments by Paion...